Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T23:02:45.520Z Has data issue: false hasContentIssue false

19 - The effect of chemotherapy, detection of minimal residual disease, and hematopoietic stem cell transplantation

from Section 2 - Neoplastic hematopathology

Published online by Cambridge University Press:  03 May 2011

By
Maria A. Proytcheva
Edited by
Maria A. Proytcheva
Maria A. Proytcheva
Affiliation:
Northwestern University Feinberg School of Medicine
Maria A. Proytcheva
Affiliation:
Northwestern University Medical School, Illinois
Get access

Summary

Introduction

As a result of combination chemotherapy administered from several months to 2–3 years, depending upon the type of malignancy and risk stratification, the cure rate in children with acute lymphoblastic leukemia (ALL) who are younger than 15 years of age has risen from less than 10% in the pre-chemotherapy era to 88% presently [1]. Moreover, the cure rate for acute myeloid leukemia (AML), although not as successful, has also markedly improved. This success came mostly as a result of randomized clinical trials conducted by the Children's Oncology Group (COG), the St. Jude Children's Research Hospital, the Medical Research Council in the United Kingdom, and the German Berlin–Frankfurt–Münster clinical trials group. However, while the chemotherapy is necessary for a cure, most of the chemotherapeutic agents have serious myelosuppressive effects resulting in short- and long-term abnormalities in the peripheral blood and bone marrow. Knowledge of these changes is essential for the proper evaluation of such specimens in children undergoing chemotherapy.

Factors affecting treatment response

The treatment response and leukemia clearance differ depending on multiple factors associated with the host response to chemotherapy. Recent studies have shown that these differences in response to drugs are due to individual genomic variations such as single nucleotide polymorphisms (SNPs), insertion, inversions, copy-number variations, epigenetic variants, or loss of heterozygosity that are able to influence the absorption, distribution, metabolism, and excretion of chemotherapeutic agents [2] (Table 19.1 [3]).

Type
Chapter
Information
Diagnostic Pediatric Hematopathology , pp. 357 - 378
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Seibel, NL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology/the Education Program of the American Society of Hematology. 2008:374–380.Google ScholarPubMed
Evans, WE, Relling, MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468.CrossRefGoogle ScholarPubMed
Pui, C-H, Relling, MV, Evans, WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Practice & Research Clinical Haematology. 2002;15:741–756.CrossRefGoogle ScholarPubMed
Lennard, L, Lilleyman, JS, Loon, J, Weinshilboum, RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225–229.CrossRefGoogle ScholarPubMed
McLeod, HL, Yu, J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Investigation. 2003;21:630–640.CrossRefGoogle ScholarPubMed
Coulthard, SA, Matheson, EC, Hall, AG, Hogarth, . The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Nucleosides, Nucleotides & Nucleic Acids. 2004;23:1385–1391.CrossRefGoogle ScholarPubMed
Den, Akker-vanMarle, ME, Gurwitz, D, Detmar, SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7:783–792.Google Scholar
Pui, C-H, Evans, WE. Treatment of acute lymphoblastic leukemia. New England Journal of Medicine. 2006;354:166–178.CrossRefGoogle ScholarPubMed
Cheok, MH, Pottier, N, Kager, L, Evans, WE. Pharmacogenetics in acute lymphoblastic leukemia. Seminars in Hematology. 2009;46:39–51.CrossRefGoogle ScholarPubMed
Leith, CP, Kopecky, KJ, Chen, IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086–1099.Google ScholarPubMed
Leith, CP, Kopecky, KJ, Godwin, J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329.Google ScholarPubMed
Foucar, K. Effects of therapy and transplantation, and detection of minimal residual disease. In Foucar, K, ed. Bone Marrow Pathology (2nd edn.). Chicago: ASCP Press; 2001, 655–681.Google Scholar
Brody, JP, Krause, JR, Penchansky, L. Bone marrow response to chemotherapy in acute lymphocytic leukaemia and acute non-lymphocytic leukaemia. Scandinavian Journal of Haematology. 1985;35:240–245.CrossRefGoogle ScholarPubMed
Muretto, P, Izzi, T, Grianti, C, Moretti, L. Histomorphologic study of bone marrow in acute leukemia following chemotherapy and autologous bone marrow transplantation. Tumori. 1983;69:239–248.CrossRefGoogle ScholarPubMed
Corazza, F, Hermans, C, Ferster, A, et al. Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatric Research. 2004;55:152–158.CrossRefGoogle ScholarPubMed
Noren-Nystrom, U, Roos, G, Bergh, A, et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia. 2007;22:504–510.CrossRefGoogle ScholarPubMed
Wittels, B. Bone marrow biopsy changes following chemotherapy for acute leukemia. American Journal of Surgical Pathology. 1980;4:135–142.CrossRefGoogle ScholarPubMed
Islam, A. Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia. Journal of Medicine. 1987;18:108–122.Google ScholarPubMed
Wilkins, BS, Bostanci, AG, Ryan, MF, Jones, DB. Haemopoietic regrowth after chemotherapy for acute leukaemia: an immunohistochemical study of bone marrow trephine biopsy specimens. Journal of Clinical Pathology. 1993;46:915–921.CrossRefGoogle ScholarPubMed
Corazza, F, Beguin, Y, Bergmann, P, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood. 1998;92:1793–1798.Google Scholar
Carlo-Stella, C, Tabilio, A, Regazzi, E, et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplantation. 1997;20:465–471.CrossRefGoogle ScholarPubMed
Cheson, BD, Bennett, JM, Kopecky, KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21:4642–4649.CrossRefGoogle Scholar
Kidd, PG, Saminathan, T, Drachtman, RA, Ettinger, LJ. Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7–14 of chemotherapy. Medical and Pediatric Oncology. 1997;29:541–543.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Borowitz, MJ, Devidas, M, Hunger, SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111:5477–5485.CrossRefGoogle ScholarPubMed
Campana, D. Minimal residual disease in acute lymphoblastic leukemia. Seminars in Hematology. 2009;46:100–106.CrossRefGoogle ScholarPubMed
Bader, P, Kreyenberg, H, Henze, GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology. 2009;27:377–384.CrossRefGoogle ScholarPubMed
Campana, D. Status of minimal residual disease testing in childhood haematological malignancies. British Journal of Haematology. 2008;143(4): 481–489.Google ScholarPubMed
Velden, VHJ, Hochhaus, A, Cazzaniga, G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–1034.CrossRefGoogle ScholarPubMed
Boeckx, N, Willemse, MJ, Szczepanski, T, et al. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia. 2002;16:368–375.CrossRefGoogle ScholarPubMed
Campana, D, Coustan-Smith, E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139–152.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
Borowitz, MJ, Pullen, DJ, Shuster, JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17:1566–1572.CrossRefGoogle ScholarPubMed
Coustan-Smith, E, Ribeiro, RC, Rubnitz, JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology. 2003;123:243–252.CrossRefGoogle ScholarPubMed
Longacre, TA, Foucar, K, Crago, S, et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood. 1989;73:543–552.Google ScholarPubMed
Lochem, EG, Wiegers, YM, Beemd, R, et al. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia. 2000;14:688–695.CrossRefGoogle ScholarPubMed
Dworzak, MN, Fritsch, G, Fleischer, C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia. 1997;11:1266–1273.CrossRefGoogle ScholarPubMed
Smedmyr, B, Bengtsson, M, Jakobsson, A, et al. Regeneration of CALLA (CD10+), TdT+ and double-positive cells in the bone marrow and blood after autologous bone marrow transplantation. European Journal of Haematology. 1991;46:146–151.CrossRefGoogle Scholar
Leitenberg, D, Rappeport, JM, Smith, BR. B-cell precursor bone marrow reconstitution after bone marrow transplantation. American Journal of Clinical Pathology. 1994;102:231–236.CrossRefGoogle ScholarPubMed
Dworzak, MN, Fritsch, G, Froschl, G, Printz, D, Gadner, H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood. 1998;92:3203–3209.Google ScholarPubMed
Pongers-Willemse, MJ, Seriu, T, Stolz, F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110–118.CrossRefGoogle Scholar
Dongen, JJ, Macintyre, EA, Gabert, JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928.CrossRefGoogle ScholarPubMed
Velden, VHJ, Boeckx, N, Wering, ER, Dongen, JJM. Detection of minimal residual disease in acute leukemia. Journal of Biological Regulators & Homeostatic Agents. 2004;18:146–154.Google ScholarPubMed
Flohr, T, Schrauder, A, Cazzaniga, G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–782.CrossRefGoogle ScholarPubMed
Velden, VHJ, Panzer-Grumayer, ER, Cazzaniga, G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21:706–713.CrossRefGoogle Scholar
Gabert, J, Beillard, E, Velden, VHJ, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17:2318–2357.CrossRefGoogle ScholarPubMed
Cilloni, D, Renneville, A, Hermitte, F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology. 2009;27:5195–5201.CrossRefGoogle ScholarPubMed
Kerst, G, Kreyenberg, H, Roth, C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. British Journal of Haematology. 2005;128:774–782.CrossRefGoogle ScholarPubMed
Duhrsen, U, Villeval, JL, Boyd, J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074–2081.Google ScholarPubMed
Lehrnbecher, T, Zimmermann, M, Reinhardt, D, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109:936–943.CrossRefGoogle ScholarPubMed
Wittman, B, Horan, J, Lyman, GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treatment Reviews. 2006;32:289–303.CrossRefGoogle ScholarPubMed
Heath, JA, Steinherz, PG, Altman, A, et al. Human granulocyte colonystimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Journal of Clinical Oncology. 2003;21:1612–1617.CrossRefGoogle Scholar
Levine, JE, Boxer, . Clinical applications of hematopoietic growth factors in pediatric oncology. Current Opinion in Hematology. 2002;9:222–227.CrossRefGoogle ScholarPubMed
Frangoul, H, Nemecek, ER, Billheimer, D, et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood. 2007;110:4584–4587.CrossRefGoogle ScholarPubMed
Lehrnbecher, T, Welte, K. Haematopoietic growth factors in children with neutropenia. British Journal of Haematology. 2002;116:28–56.CrossRefGoogle ScholarPubMed
Bonilla, MA, Gillio, AP, Ruggeiro, M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. New England Journal of Medicine. 1989;320:1574–1580.CrossRefGoogle ScholarPubMed
Kerrigan, DP, Castillo, A, Foucar, K, Townsend, K, Neidhart, J. Peripheral blood morphologic changes after high-dose antineoplastic chemotherapy and recombinant human granulocyte colony-stimulating factor administration. American Journal of Clinical Pathology. 1989;92:280–285.CrossRefGoogle ScholarPubMed
Harris, AC, Todd, WM, Hackney, MH, Ben-Ezra, J. Bone marrow changes associated with recombinant granulocyte-macrophage and granulocyte colony-stimulating factors. Discrimination of granulocytic regeneration. Archives of Pathology & Laboratory Medicine. 1994;118:624–629.Google ScholarPubMed
Handgretinger, R, Turner, V, Barfield, R. Hematopoietic stem cell transplantation. In Pui, C-H, ed. Childhood Leukemias (2nd edn.). New York: Cambridge University Press; 2006, 599–624.CrossRefGoogle Scholar
Barfield, RC, Kasow, KA, Hale, GA. Advances in pediatric hematopoietic stem cell transplantation. Cancer Biology & Therapy. 2008;7:1533–1539.CrossRefGoogle ScholarPubMed
Buckley, RH, Schiff, SE, Schiff, RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. New England Journal of Medicine. 1999;340:508–516.CrossRefGoogle ScholarPubMed
Lawson, SE, Roberts, IAG, Amrolia, P, et al. Bone marrow transplantation for beta-thalassaemia major: the UK experience in two paediatric centres. British Journal of Haematology. 2003;120:289–295.CrossRefGoogle ScholarPubMed
Vermylen, C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Reviews. 2003;17:163–166.CrossRefGoogle ScholarPubMed
Willasch, A, Hoelle, W, Kreyenberg, H, et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica. 2006;91:788–794.Google ScholarPubMed
Kletzel, M, Katzenstein, HM, Haut, PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study. Journal of Clinical Oncology. 2002;20:2284–2292.CrossRefGoogle ScholarPubMed
Marion, AMW, Thiele, J, Kvasnicka, HM, Tweel, JG. Morphology of the bone marrow after stem cell transplantation. Histopathology. 2006;48:329–342.CrossRefGoogle ScholarPubMed
Frimberger, AE, Stering, AI, Quesenberry, PJ. An in vitro model of hematopoietic stem cell homing demonstrates rapid homing and maintenance of engraftable stem cells. Blood. 2001;98:1012–1018.CrossRefGoogle Scholar
Whetton, AD, Graham, GJ. Homing and mobilization in the stem cell niche. Trends in Cell Biology. 1999;9:233–238.CrossRefGoogle ScholarPubMed
Choi, K, Kennedy, M, Kazarov, A, Papadimitriou, JC, Keller, G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125:725–732.Google ScholarPubMed
Chasis, JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Current Opinion in Hematology. 2006;13:137–141.CrossRefGoogle ScholarPubMed
Thiele, J, Kvasnicka, HM, Beelen, DW, et al. Macrophages and their subpopulations following allogeneic bone marrow transplantation for chronic myeloid leukaemia. Virchows Archiv. 2000;437:160–166.CrossRefGoogle ScholarPubMed
Kruskall, MS. Transfusion support for the oncology patients. In Simon, TL, Dzik, WH, Snyder, EL, Stowell, CP, Stausss, RG, eds. Rossi's Principles of Transfusion Medicine (3rd edn.). Philadelphia, PA: Lippincott, Williams & Wilkins; 2002, 498–513.Google Scholar
Maeda, T, Shiozawa, E, Mayumi, H, et al. Histopathology of bone marrow reconstitution after umbilical cord blood transplantation for hematological diseases. Pathology International. 2008;58:126–132.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×